Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06656468
Enrolling by invitation Observational

Outcome of Patients Undergoing Leadless Pacemaker Implantaton

NCT06656468 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Ospedaliera Cardinale G. Panico
Phase
Observational
Started
2019-09-01
Last updated
2024-10-24

Condition(s) studied

Bradyarrhythmias

Investigational drug(s) / intervention(s)

Pacemaker and defibrillator

Pacemaker and defibrillator: Leadless pacemaker implantation procedure performed accordng to usual clinical practice. The indication for pacemaker implantation will be based on current guidelines.

Study summary

Observational study aimed to evaluate the rate and of complications related to lealdless pacemaker implantation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients with indication for leadless pacemaker implantation according to current Guidelines on cardiac pacing. Exclusion Criteria: * inability to sign informed consent

Primary outcome measure(s)

  • Acute complications — From date of implantation until the date of first documented complication, assessed up to 30 days.
    Acute complications related to leadless pacemaker implantation

Trial sites (1)

FacilityCityRegionStatus
Azienda Ospedaliera "Card. G. Panico" Tricase Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06656468 on ClinicalTrials.gov ↗ ← All trials in Italy